David W. Gray - Concepedia

Author

David W. Gray

University of Dundee ORCID

Also Known As

D W Gray, D. W. GRAY, D.W. Gray, David Gray, David W Gray, David W. Gray, Gray, David W.

114

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

University of Dundee GlaxoSmithKline (United Kingdom)GlaxoSmithKline (Spain)Research Triangle Park Foundation Wellcome Centre for Anti-Infectives Research

About

David W. Gray is an author at University of Dundee specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	23	2.5K
2	Natural Sciences	6	6	311
3	Engineering	2	2	88
4	Health Sciences	1	1	25
5	Allergy	1	1	143

David W. Gray

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Mice lacking MHC class II molecules Dominic Cosgrove, David W. Gray, Andrée Dierich, Cell HistocompatibilityKnockout MouseImmunogeneticsAutoimmune DiseaseImmunology	1991	849
A novel multiple-stage antimalarial agent that inhibits protein synthesis Beatriz Baragaña, Irene Hallyburton, Neil R. Norcross, Nature Antiparasitic AgentMedicineMalariaPharmacologyProtein Synthesis	2015	452
New Compound Sets Identified from High Throughput Phenotypic Screening Against Three Kinetoplastid Parasites: An Open Resource Imanol Peña, Marlene Manzano, Juan Cantizani, Scientific Reports	2015	248
Novel signal transduction pathway mediating endothelium‐dependent β‐adrenoceptor vasorelaxation in rat thoracic aorta David W. Gray, Ian Marshall British Journal of Pharmacology	1992	177
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition Susan Wyllie, Stephen Brand, Michael G. Thomas, Proceedings of the National Academy of Sciences	2019	165
Human α‐calcitonin gene‐related peptide stimulates adenylate cyclase and guanylate cyclase and relaxes rat thoracic aorta by releasing nitric oxide David W. Gray, Ian Marshall British Journal of Pharmacology	1992	143
Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease Mark Salter, Keith Biggadike, Joyce Matthews, American Journal of Physiology-Lung Cellular and Molecular Physiology AsthmaInflammatory Lung DiseaseLung InflammationAllergy MedicineImmunology	2007	143
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis Susan Wyllie, Michael G. Thomas, Stephen Patterson, Nature Drug TargetCyclin-dependent Kinase 12Parasitic ProtozoaMedicineImmunology	2018	142
Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay Manu De Rycker, Irene Hallyburton, John Thomas, Antimicrobial Agents and Chemotherapy	2013	141
Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis Beatriz Baragaña, Barbara Forte, Ryan Choi, Proceedings of the National Academy of Sciences	2019	132

Page 1